INSIGHTS ON CELL & GENE THERAPY LOGISTICS

• Compliance, Costs, And Site Readiness In CAR-T Clinical Trials

  Navigate CAR-T trial complexity: uncover key compliance, budgeting, and site readiness strategies to ensure safe, efficient, and successful patient care.

• Managing Operational Challenges In CAR-T Clinical Trial Logistics

  Coordinating CAR-T trials means managing tight timelines, cryogenic handling, staffing gaps, and chain-of-identity risks where even small missteps can delay care.

• How To Select The Right Fill-Finish CDMO For Phase I–II

  Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

• Scientific Staffing

  A customizable scientific‑insourcing model delivers flexible onsite staffing, boosts lab capacity, reduces hiring burdens, and supports routine scientific work with trained professionals.

• Technical Field Services

  A flexible technical field‑services program offers multi‑vendor laboratory instrument support, facility services, relocations, and environmental qualifications to optimize operations, reduce risk, and maintain compliance.

• Defragmenting The Pre‑Clinical Supply Chain

  Fragmented pre‑clinical supply chains create avoidable delays and risks; unifying cryopreservation, logistics, and storage early improves consistency, reduces operational gaps, and supports smoother progression into clinical phases.

• Investors Trust Strong Supply Chains

  Investors now value operational maturity as much as science. Early, intentional supply‑chain planning shows scalability, lowers risk, and builds confidence in reliable growth.

• Green Supply Chains Rarely Start With A Pledge; Target Waste Instead

  Effective sustainability strategies in pharma supply chains reduce rework and overage. Three leakage points offer the most practical starting point for rooting out waste.

• Best Practices For Managing The Logistics And Distribution Of CGTs

  Site infrastructure, formulary timelines, and storage capabilities create barriers between approval and patient access. Planning for these operational realities separates successful launches from stalled ones.

• U.S. Pharma Tariffs And MFN In 2026: Manufacturing And Procurement Impact

  Beroe Inc.'s Mathini Ilancheran discusses the 2025 U.S. pharma tariff framework and translates it into actionable procurement and outsourcing responses.